Anti-Mullarian Hormone As A Diagnostic Marker of Polycystic Ovary Syndrome
DOI:
https://doi.org/10.51253/pafmj.v74i1.9166Keywords:
Anti-mullerian hormone, Infertility, Obesity, Polycystic ovary syndromeAbstract
Objective: To determine the utility of Anti-mullerian hormone (AMH) as a diagnostic marker of Polycystic ovarian syndrome
(PCOS).
Study Design: Comparative cross-sectional study
Place and Duration of the Study: Department of Chemical Pathology and Endocrinology, Army Medical College Rawalpindi, Pakistan in collaboration with the Department of Gynaecology and Obstetrics, Pak-Emirates Military Hospital, Rawalpindi Pakistan from Jan 2019 to Jan 2020.
Methodology: The study recruited 30 cases of PCOS and 30 age-matched Controls using Rotterdam criteria. Anti-mullerian
hormone (AMH) and testosterone were measured for both the study groups.
Results: Receiver operator curve (ROC) analysis confirmed the utility of anti-mullerian hormone in diagnosing patients with
PCOS. The AUC was 0.754 with 95% CI (0.629-0.880). The optimal cut-off point was 3.22ng/mL (Sensitivity 80%, Specificity
66.7%).
Conclusion: The AMH is appraised as an independent screening marker for PCOS patients. Using this single parameter can
decrease the patient's inconvenience and financial burden on the health care system and the patient.
Downloads
References
Stracquadanio M, Ciotta L, Palumbo MA. Relationship between
serum anti-Mullerian hormone and intrafollicular AMH levels in
PCOS women. Gynecol Endocrinol 2018; 34(3): 223-228.
https://doi.org/10.1080/09513590.2017.1381838.
Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary
Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac J
Cancer Prev 2017; 18(1): 17-21.
https://doi.org/10.22034/APJCP.2017.18.1.17.
Hoyos LR, Visser JA, McLuskey A, Chazenbalk GD, Grogan TR,
Dumesic DA. Loss of anti-Müllerian hormone (AMH)
immunoactivity due to a homozygous AMH gene variant
rs10417628 in a woman with classical polycystic ovary
syndrome (PCOS). Hum Reprod 2020; 35(10): 2294-2302.
https://doi.org/10.1093/humrep/deaa199.
Sahmay S, Aydogan Mathyk B, Sofiyeva N, Atakul N, Azemi A,
Erel T. Serum AMH levels and insulin resistance in women with
PCOS. Eur J Obstet Gynecol Reprod Biol 2018; 224: 159-164.
https://doi.org/10.1016/j.ejogrb.2018.03.007.
Vembu R, Reddy NS. Serum AMH Level to Predict the Hyper
Response in Women with PCOS and Non-PCOS Undergoing
Controlled Ovarian Stimulation in ART. J Hum Reprod Sci 2017;
(2): 91-94. https://doi.org/10.4103/jhrs.JHRS_15_16.
Saxena U, Ramani M, Singh P. Role of AMH as Diagnostic Tool
for Polycystic Ovarian Syndrome. J Obstet Gynaecol India 2018;
(2): 117-122. https://doi.org/10.1007/s13224-017-1066-4.
Shrikhande L, Shrikhande B, Shrikhande A. AMH and Its
Clinical Implications. J Obstet Gynaecol India 2020; 70(5): 337-
https://doi.org/10.1007/s13224-020-01362-0.
Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian
Hormone: Above and Beyond Conventional Ovarian Reserve
Markers. Dis Markers 2016; 2016: 5246217.
https://doi.org/10.1155/2016/5246217.
Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic
ovary syndrome: the role of hyperandrogenism. Front Horm Res
; 40: 22-27. https://doi.org/10.1159/000341679.
Abbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Roberts
R, et al. Anti-Müllerian hormone (AMH) in the Diagnosis of
Menstrual Disturbance Due to Polycystic Ovarian Syndrome.
Front Endocrinol 2019; 10: 656.
https://doi.org/10.3389/fendo.2019.00656.
Dewailly D. Diagnostic criteria for PCOS: Is there a need for a
rethink? Best Pract Res Clin Obstet Gynaecol 2016; 37: 5-11.
https://doi.org/10.1016/j.bpobgyn.2016.03.009.
Shi Y, Li L, Zhou J, Sun J, Chen L, Zhao J, et al. Efficacy of
electroacupuncture in regulating the imbalance of AMH and
FSH to improve follicle development and hyperandrogenism in
PCOS rats. Biomed Pharmacother 2019; 113: 108687.
https://doi.org/10.1016/j.biopha.2019.108687.
Amer SA, Shamy TTE, James C, Yosef AH, Mohamed AA. The
impact of laparoscopic ovarian drilling on AMH and ovarian
reserve: a meta-analysis. Reproduction 2017; 154(1): R13-R21.
https://doi.org/10.1530/REP-17-0063.
Bhide P, Kulkarni A, Dilgil M, Dhir P, Shah A, Gudi A, et al.
Phenotypic variation in anti-Mullerian hormone (AMH)
production per follicle in women with polycystic ovary
syndrome (PCOS) and isolated polycystic ovarian morphology
(PCOM): an observational cross-sectional study. Gynecol
Endocrinol 2017; 33(10): 801-806.
https://doi.org/10.1080/09513590.2017.1320377.
Wiweko B, Indra I, Susanto C, Natadisastra M, Hestiantoro A.
The correlation between serum AMH and HOMA-IR among
PCOS phenotypes. BMC Res Notes 2018; 11(1): 114.
https://doi.org/10.1186/s13104-018-3207-y.
Peigné M, Pigny P, Pankhurst MW, Drumez E, Loyens A,
Dewailly D, et al. The proportion of cleaved anti-Müllerian
hormone is higher in serum but not follicular fluid of obese
women independently of polycystic ovary syndrome. Reprod
Biomed Online 2020; 41(6): 1112-1121.
https://doi.org/10.1016/j.rbmo.2020.07.020.
Calzada M, López N, Noguera JA, Mendiola J, Hernández AI,
Corbalán S, et al. AMH in combination with SHBG for the
diagnosis of polycystic ovary syndrome. J Obstet Gynaecol 2019;
(8): 1130-1136.
https://doi.org/10.1080/01443615.2019.1587604.
Gupta M, Yadav R, Mahey R, Agrawal A, Upadhyay A,
Malhotra N, et al. Correlation of body mass index (BMI), antimullerian hormone (AMH), and insulin resistance among
different polycystic ovary syndrome (PCOS) phenotypes - a
cross-sectional study. Gynecol Endocrinol 2019; 35(11): 970-973.
Downloads
Published
Issue
Section
How to Cite
